Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.
暂无分享,去创建一个
Chao Cheng | Chao Cheng | S. Fiering | F. Varn | Yue Wang | Frederick S Varn | Steven Fiering | Yue Wang | David W Mullins | D. Mullins
[1] Chao Cheng,et al. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles , 2016, Nature Communications.
[2] E. Yang,et al. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation , 2013, Nature Immunology.
[3] Pornpimol Charoentong,et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.
[4] J. Markowitz,et al. Myeloid-derived suppressor cells in breast cancer , 2013, Breast Cancer Research and Treatment.
[5] Tom C. Freeman,et al. Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.
[6] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[8] Fengzhu Sun,et al. Inferring activity changes of transcription factors by binding association with sorted expression profiles , 2007, BMC Bioinform..
[9] J. Wolchok,et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ian O Ellis,et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Engelhardt,et al. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. , 2012, Trends in immunology.
[13] L. Sempere,et al. VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy , 2014, Cancer Immunology Research.
[14] I. Mercier,et al. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators , 2015, Front. Immunol..
[15] Chao Cheng,et al. Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia , 2015, Scientific Reports.
[16] M. Ernstoff,et al. VISTA is an immune checkpoint molecule for human T cells. , 2014, Cancer research.
[17] H. Kölbl,et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.
[18] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[19] A. Regev,et al. Transcriptome Analysis Identifies Regulators of Hematopoietic Stem and Progenitor Cells , 2013, Stem cell reports.
[20] Scott D. Brown,et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.
[21] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[22] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.
[23] D. Koller,et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems , 2013, Proceedings of the National Academy of Sciences.
[24] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[25] H Nagura,et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.
[26] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[27] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[28] R. Noelle,et al. VISTA Regulates the Development of Protective Antitumor Immunity. , 2014, Cancer research.
[29] Or Zuk,et al. Identification of transcriptional regulators in the mouse immune system , 2013, Nature Immunology.
[30] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[31] E. Suchman,et al. The American Soldier: Adjustment During Army Life. , 1949 .
[32] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[33] J. Galon,et al. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. , 2015, Cancer research.
[34] Ash A. Alizadeh,et al. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .
[35] V. Reuter,et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.
[36] D. Gabrilovich,et al. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. , 2015, The Journal of clinical investigation.
[37] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] A. Butte,et al. Systematic pan-cancer analysis of tumour purity , 2015, Nature Communications.
[39] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[40] Christina Appin,et al. Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class , 2013, Clinical Cancer Research.
[41] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[42] F. Markowetz,et al. Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling , 2012, Science Translational Medicine.
[43] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[44] B. Ammori,et al. Myeloid‐derived suppressor cells in cancer: recent progress and prospects , 2013, Immunology and cell biology.
[45] S. Gabriel,et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.
[46] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[47] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[48] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[49] C. Perou,et al. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. , 2016, Journal of the National Cancer Institute.
[50] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[51] Halli E. Miller,et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses , 2015, Proceedings of the National Academy of Sciences.